Market Summary
Diabetic Retinopathy Market Overview
Diabetic Retinopathy market size was valued at USD 8.62 billion in 2023. The Diabetic Retinopathy market industry is projected to grow from USD 8.14 billion in 2024 to USD 15.36 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.72% during the forecast period (2024 - 2032).
The diabetic retinopathy market is being driven by the rising prevalence of diabetes worldwide, which increases the incidence of diabetic retinopathy. Advances in diagnostic technology, such as optical coherence tomography (OCT) and fundus photography, improve early detection and treatment outcomes. Furthermore, the increased emphasis on customized medicine and novel medication therapy, such as anti-VEGF medicines, is broadening therapeutic possibilities. However, the market faces barriers, such as the high cost of modern therapies and a lack of awareness in rural areas. Emerging markets offer opportunities for increased healthcare access and investment in revolutionary therapeutics such as gene therapy and AI-based diagnostic tools, which have the potential to improve diabetic retinopathy market management and generate new revenue streams. Collaborations between pharmaceutical companies and healthcare providers may also accelerate market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Diabetic Retinopathy Market Trends
Advances in diagnostic technologies, such as optical coherence tomography (OCT) and fundus photography fuels market growth
Advances in diagnostic technologies, like as Optical Coherence Tomography (OCT) and fundus photography, have significantly increased the diabetic retinopathy market by improving diagnostic accuracy, speed, and accessibility. OCT, a non-invasive imaging tool, produces high-resolution cross-sectional images of the retina, allowing clinicians to detect early signs of diabetic macular edema and retinal damage, both of which are significant predictors of diabetic retinopathy market. OCT enables precise monitoring of disease progression, making it critical for timely intervention and tailored treatment programs. Fundus photography, on the other hand, produces precise photographs of the retina, allowing healthcare providers to detect abnormalities such as hemorrhages, microaneurysms, and exudates, all of which are associated with diabetic retinopathy market. These technologies have increased early detection, which is critical for reducing eyesight loss in diabetics. Furthermore, its integration with AI and machine learning algorithms improves diagnostic accuracy, enabling automated screening and diagnosis in rural or underserved locations. As a result, more people are able to receive early diagnosis and treatment, which leads to improved outcomes. The accessibility and affordability of these new technologies are likely to boost their acceptance, positioning them as significant drivers of diabetic retinopathy market growth.
Diabetic Retinopathy Market Segment Insights
Diabetic Retinopathy Market Type Insights
The Diabetic Retinopathy market segmentation, based on type, includes Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). The non-proliferative diabetic retinopathy (NPDR) segment dominated the market in 2023. The growing geriatric population and rising diabetes-related blindness rates are the primary reasons for its high prevalence. NPDR, also known as background retinopathy, is a common diabetic eye disease and one of the major causes of blindness in adults. It usually progresses from mild to moderate, resulting in serious eye disorders. NPDR is largely defined by microaneurysms (microscopic blood-filled bulges in artery walls) that leak into the retina. Although non-proliferative retinopathy is not a vision-threatening disorder, it can cause diabetic macular edema (swelling in the macula), leading to vision loss. As the severity of NPDR increases, so does the likelihood of developing vision-threatening proliferative diabetic retinopathy market.
Diabetic Retinopathy Market Treatment Insights
The Diabetic Retinopathy market segmentation, based on treatment, includes pharmacological therapies, laser treatment, and surgery. The pharmacological therapies segment is further divided into Anti-VEGF Injections and Corticosteroids. The pharmacological therapies segment dominated the market in 2023. The pharmacological therapies segment of the diabetic retinopathy (DR) market is being driven by the increasing usage of drugs to manage the condition and avoid visual loss. Anti-vascular endothelial growth factor (anti-VEGF) medicines, such as ranibizumab and aflibercept, are important treatments because they minimize retinal edema and prevent abnormal blood vessel growth. Steroid injections, such as dexamethasone, can also help to reduce inflammation in diabetic macular edema. In addition, intravitreal injections and novel medication candidates that target inflammatory pathways and retinal regeneration are being developed. The efficacy of these medicines in improving visual results and decreasing disease progression is driving widespread use, resulting in market growth.
Figure 2: Diabetic Retinopathy Market, by Treatment, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Diabetic Retinopathy Market End User Insights
The Diabetic Retinopathy market segmentation, based on end user, includes hospitals & clinics, ophthalmology centers, and research institutes. The hospitals & clinics segment dominated the market in 2023, while the ophthalmology centers segment is projected to be the fastest-growing segment during the forecast period, 2024–2032. The hospitals and clinics are critical to the diabetic retinopathy (DR) market since these facilities serve as key diagnostic and treatment centers for this condition. Hospitals and clinics use advanced diagnostic technologies such as OCT and fundus photography to provide comprehensive screenings, early detection, and timely interventions. Laser therapy, intravitreal injections, and surgical procedures are among the therapies provided by specialized ophthalmology departments, which are adapted to the specific needs of each patient. The rising prevalence of diabetes and increased knowledge of DR control are driving patient visits to these healthcare facilities. This market is predicted to grow significantly due to increased availability to quality eye care and specialized therapies.
Diabetic Retinopathy Market Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America dominates the diabetic retinopathy (DR) market, owing to its high diabetes incidence and advanced healthcare infrastructure. The region benefits from cutting-edge diagnostic technology, like as OCT and fundus imaging, which allow for early and reliable detection of diabetic retinopathy. Furthermore, the availability of a wide range of pharmaceutical treatments, including anti-VEGF medicines, helps to enhance disease management. The presence of large pharmaceutical companies, as well as ongoing research into novel medicines, drives market growth. Furthermore, increased awareness of diabetic retinopathy and government programs for diabetes care contribute to the growth of the diabetic retinopathy market in North America.
Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 3: DIABETIC RETINOPATHY MARKET BY REGION 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Diabetic Retinopathy market accounted for the second-largest market share due to well-established healthcare infrastructure, growing healthcare industry, drives the market. Furthermore, the Germany Diabetic Retinopathy provider attributed to hold the largest market share, and the France Diabetic Retinopathy providers is projected be the fastest growing market in the Europe region.
The Asia-Pacific Diabetic Retinopathy market is expected to be the fastest growing from 2024 to 2032 due to rising investments in AI technology, growing geriatric population, increasing healthcare expenditure and government Initiatives and investments. Moreover, China Diabetic Retinopathy accounted to hold the largest market share, and the India Diabetic Retinopathy is projected to be the fastest growing market in the Asia-Pacific region.
Diabetic Retinopathy Key Market Players & Competitive Insights
The Diabetic Retinopathy market is distinguished by the presence of numerous , regional, and local players catering to diabetic retinopathy. Furthermore, the rising number of ai-powered medical imaging start- ups and the growing strategic initiatives by market players is further driving the growth of Diabetic Retinopathy market during the forecast period. Pharmaceutical companies, healthcare providers, and technology developers collaborate and partner to deliver comprehensive Diabetic Retinopathy management solutions. The goal is to increase access to therapy in emerging areas while also improving diagnostic tool precision. Ongoing research into gene therapies, stem cell treatments, and next-generation medications is driving up competition and positioning these companies for long-term success in the Diabetic Retinopathy market.
Novartis AG (Novartis) is a healthcare company that specializes in the development, manufacture, and distribution of pharmaceutical products, including both generic and name-brand products, as well as eye care products. Solid tumors, immunological disorders, infections, neurological disorders, ophthalmic and respiratory diseases, oncology, cardiovascular diseases, dermatological conditions, and hematologic diseases, Sickle cell anemia, are among the many illnesses for which it provides medication. The company offers generic drugs and biosimilars through Sandoz. Through The Novartis Institutes for Biomedical Research (NIBR), Novartis carries out research in a number of illness areas. Through a network of subsidiaries and offices, the company operates throughout the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
Moreover, In October 2021, Novartis announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME). Additionally, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) accepted an application for Beovu in the treatment of DME. Regulatory decisions for Beovu in DME are expected in mid-2022 for the US and Europe.
Key Companies in the Diabetic Retinopathy market includes.
- Novartis AG
- Bayer AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Carl Zeiss
- Optos
- Genentech, Inc.
- Eli Lilly and Company
- Viatris
Diabetic Retinopathy Market Industry Developments
In September 2021, AbbVie and REGENXBIO Inc. announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.Diabetic Retinopathy Market Segmentation
Diabetic Retinopathy Market Type Outlook
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
Diabetic Retinopathy Market Treatment Outlook
-
Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
Diabetic Retinopathy Market End User Outlook
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
Diabetic Retinopathy Market Regional Outlook
North America- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East
- Africa
- Latin America
Market Size & Forecast
|
Report Attribute/Metric |
Details |
|
Market Size 2023 |
USD 8.62 billion |
|
Market Size 2024 |
USD 8.14 billion |
|
Market Size 2032 |
USD 15.36 billion |
|
Compound Annual Growth Rate (CAGR) |
6.72% (2024-2032) |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2019 to 2022 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Treatment, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
|
Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, and South Korea |
|
Key Companies Profiled |
· KonNovartis AG · Bayer AG · F. Hoffmann-La Roche Ltd · Regeneron Pharmaceuticals Inc. · Carl Zeiss · Optos · Genentech, Inc. · AbbVie · Eli Lilly and Company · Viatris |
Major Players
Market Segmentation TabDiabetic Retinopathy Type Outlook (USD Billion, 2019-2032)
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- North America Outlook (USD Billion, 2019-2032)
- North America Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- North America Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- North America Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- US Outlook (USD Billion, 2019-2032)
- US Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- US Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- US Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Canada Outlook (USD Billion, 2019-2032)
- Canada Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Canada Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Canada Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Europe Outlook (USD Billion, 2019-2032)
- Europe Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Europe Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Europe Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Germany Outlook (USD Billion, 2019-2032)
- Germany Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Germany Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Germany Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- France Outlook (USD Billion, 2019-2032)
- France Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- France Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- France Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Italy Outlook (USD Billion, 2019-2032)
- Italy Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Italy Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Italy Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Spain Outlook (USD Billion, 2019-2032)
- Spain Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Spain Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Spain Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Rest of Europe Outlook (USD Billion, 2019-2032)
- Rest of Europe Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Rest of Europe Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Rest of Europe Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Asia-Pacific Outlook (USD Billion, 2019-2032)
- Asia-Pacific Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Asia-Pacific Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Asia-Pacific Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- China Outlook (USD Billion, 2019-2032)
- China Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- China Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- China Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Japan Outlook (USD Billion, 2019-2032)
- Japan Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Japan Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Japan Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- India Outlook (USD Billion, 2019-2032)
- India Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- India Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- India Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- South Korea Outlook (USD Billion, 2019-2032)
- South Korea Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- South Korea Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- South Korea Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Australia Outlook (USD Billion, 2019-2032)
- Australia Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Australia Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Australia Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)
- Rest of Asia-Pacific Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Rest of Asia-Pacific Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Rest of Asia-Pacific Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Rest of the World Outlook (USD Billion, 2019-2032)
- Rest of the World Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Rest of the World Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Rest of the World Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Middle East Outlook (USD Billion, 2019-2032)
- Middle East Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Middle East Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Middle East Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Africa Outlook (USD Billion, 2019-2032)
- Africa Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Africa Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Africa Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Latin America Outlook (USD Billion, 2019-2032)
- Latin America Diabetic Retinopathy by Type
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Proliferative Diabetic Retinopathy (PDR)
- Latin America Diabetic Retinopathy by Treatment
- Pharmacological Therapies
- Anti-VEGF Injections
- Corticosteroids
- Laser Treatment
- Surgery
- Pharmacological Therapies
- Latin America Diabetic Retinopathy by End User
- Hospitals & Clinics
- Ophthalmology Centers
- Research Institutes
- Rest of the World Diabetic Retinopathy by Type
- Asia-Pacific Diabetic Retinopathy by Type
- Europe Diabetic Retinopathy by Type
- North America Diabetic Retinopathy by Type
Leave a Comment